Rosenbaum D
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
PreprintPsychedelics
What do we mean by “Psychedelic Knowledge” in Medical Education? A Scoping Review and Taxonomy of Educational Representations
ArticlePsilocybin
Psilocybin for Fear of Cancer Recurrence.
ArticlePsilocybin
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.
ArticlePsychedelics
The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.
ArticlePsychedelics
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.
ArticlePsilocybin
<i>Letter to the Editor:</i> Will Psilocybin-Assisted Therapy Reduce the Incidence of Medical Assistance in Dying?
ArticlePsychedelics
Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations.
ArticlePsychedelics
Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities.
ArticlePsilocybin
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
ArticlePsychedelics
Psychedelics for psychological and existential distress in palliative and cancer care.
ArticlePsilocybin
Psychedelic microdosing benefits and challenges: an empirical codebook.
ArticlePsilocybin